drugset / Trial / NCT00082173

Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis

NCT00082173 ↗

Phase 2 Completed 170 enrolled Johns Hopkins University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively treat TB.

Timeline

Start
2004-10
Primary completion
2007-09
Completion
2008-09

Outcome

Met primary endpoint

paper 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17.2%, 95% CI 2.8-31.7; p=0.03). PMID 19345831 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg —

Indications